Abstract 51P
Background
Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13. Fractionations to investigate early and four year late side effects of hypofractionated postmastectomy radiation therapy (HFRT-PM) of 39 Gy in 13 fractions over 3 weeks.
Methods
We retrospectively analyzed characteristics and outcomes of patients with stage II to III breast cancer treated with HFRT-PM between February 2019 and February 2023 during the COVID-19 pandemic. The selected patients did not have any previously diagnosed heart or lung disease. Treatment provided in 13 fractions of 3 Gy per fraction. The treatment techniques were applied by using 3-dimensional conformal radiation therapy and IMRT of the chest wall with regional nodal volume if required. The end point was freedom from any grade 3 or higher toxicities.
Results
We identified 730 patients with a median follow-up of 4 year. About two-third of the patient (66.6%) had the disease located in the left side. Regional nodal irradiation was done in 84.1% of patients. In multivariate analysis, regional lymph node involvement (≥4 nodes) was associated with worse locoregional control (hazard ratio, 1.68; 95% confidence interval, 1.06-2.67; P = .03) and overall survival (hazard ratio, 2.16; 95% confidence interval, 1.59-2.95; P < .001). The toxicities were acceptable. After a four-year follow -up, there are no grade 3 or 4 toxicities. The incidence of early skin reactions (13% grade 2) cardiac disorders (1.5%), and symptomatic lung fibrosis (1.7%) was low during follow-up. The cumulative rate of arm lymphedema was 2.1% and considered severe in 40 patients (0.05%).
Conclusions
The early results of this study show that HFRT-PM of 39 Gy in 13 fractions over 3 weeks seems safe, but long-term results need to be observed and highlighting the need for long-term follow-up and for randomized trials for hypofractionated radiation therapy postmastectomy especially for young patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract